digest
Short Summary
Main recommendation: To lower apoB, rely primarily on pharmacology, using modern lipid-lowering drugs such as PCSK9 inhibitors, bempedoic acid with ezetimibe, and low-dose statins, with diet (cutting carbohydrates and saturated fat) as a less potent supporting lever. The speaker argues that megadose statins are no longer necessary because newer tools achieve greater reductions with fewer side effects.
Key Points
- Exercise has no meaningful impact on lipoprotein-related ASCVD risk factors, according to the speaker, though it helps in other ways.
- Diet offers two levers: sharply reducing carbohydrates lowers triglycerides, and sharply reducing saturated fat lowers cholesterol synthesis and lets the liver pull more LDL out of circulation.
- The speaker's own target apoB is 30 to 40 mg/dL, which he says requires medication; his baseline without drugs is about 90 to 100 mg/dL.
- Statin efficacy plateaus around a quarter of the maximum dose; for rosuvastatin, about 85% of the maximum apoB reduction occurs at 5 mg and the maximum is reached near 10 mg.
- A drug under development that targets Lp(a) is in phase three testing for secondary prevention, and it may not be approved for primary prevention at first.
Details Worth Noting
- Concrete instructions: Reduce carbohydrates substantially to lower triglycerides, which the speaker says lowers the apoB burden. Reduce saturated fat substantially to reduce cholesterol synthesis and encourage LDL receptor activity. If using statins, start with low doses (around 5 to 10 mg rosuvastatin), since higher doses add side effects with little added benefit. If a statin is needed, try a few different ones (the speaker mentions pitavastatin, rosuvastatin, and Crestor) to find the one with the fewest side effects.
- Ezetimibe blocks the NPC1L1 transporter, reducing reabsorption of cholesterol in the gut. Bempedoic acid is a prodrug activated in the liver that inhibits cholesterol synthesis only in the liver, making it less potent than statins but more selective.
- Statin side effects the speaker lists are muscle aches, elevated liver transaminases, and insulin resistance; two of these are objectively measurable.
- PCSK9 inhibitor cost has fallen by more than 50% since launch eight years ago, and a shot given once every six months is in development.
- The speaker notes that these drugs are expensive, whereas statins are not, which may matter for young people choosing treatment.
Bottom Line
Lowering apoB effectively usually requires medication, and newer options let most people avoid high-dose statins; diet helps but is typically not enough on its own. This is the speaker's personal view and not professional medical advice.
